SCHEMBL5856339

SCHEMBL5856339

CC(C)(OCCCCCCc1coc(-c2ccccc2)n1)C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
PPARG P37231 8/20 0.64
PPARA Q07869 8/20 0.64
PPARD Q03181 1/20 0.64
FFAR1 O14842 1/20 0.47
CYP4F2 P78329 1/20 0.42
CYP4A11 Q02928 1/20 0.42
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5858533 1.00 PPARG (0.64) PPARGPPARAPPARDFFAR1CYP4F2
SCHEMBL5857029 1.00 PPARG (0.64) PPARGPPARAPPARDFFAR1CYP4F2
SCHEMBL5855844 0.90 PPARA (0.53) PPARGPPARAPPARDFFAR1CYP4F2
SCHEMBL5857569 0.90 PPARA (0.53) PPARGPPARAPPARDFFAR1CYP4F2
SCHEMBL5858343 0.90 PPARA (0.53) PPARGPPARAPPARDFFAR1LMNA
SCHEMBL5856115 0.90 PPARA (0.53) PPARGPPARAPPARDFFAR1CYP4F2
SCHEMBL5858433 0.90 PPARA (0.53) PPARGPPARAPPARDFFAR1LMNA
SCHEMBL5858320 0.90 PPARA (0.53) PPARGPPARAPPARDFFAR1LMNA
SCHEMBL27563408 0.88 PPARA (0.51) PPARGPPARAPPARDFFAR1CYP4F2
SCHEMBL5858411 0.79 PPARA (0.42) PPARGPPARAPPARDALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7144906-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-12-05 US disclosed
US-7030143-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-04-18 US disclosed
US-7022723-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-04-04 US disclosed
EP-1634876-A2 Heterocyclic compounds for the treatment of hyperlipidemia agents Nippon Shinyaku Co., Ltd. (JP) 2006-03-15 EP disclosed
US-6998412-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-02-14 US disclosed
CN-1238347-C Heterocyclic derivatives NIPPON SHINYAKU CO LTD (JP) 2006-01-25 CN disclosed
US-20050009785-A1 Heterocyclic compounds KUWABARA KENJI (JP) 2005-01-13 US disclosed
US-20050009892-A1 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2005-01-13 US disclosed
US-20040162325-A1 Heterocyclic compounds KUWABARA KENJI (JP) 2004-08-19 US disclosed
US-20030166697-A1 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2003-09-04 US disclosed
CN-1430612-A Hete rocyclic derivatives NIPPON SHINYAKU CO LTD (JP) 2003-07-16 CN disclosed
EP-1295875-A1 HETEROCYCLIC COMPOUNDS Nippon Shinyaku Co., Ltd. (JP) 2003-03-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009785-A1 Heterocyclic compounds LIPC, GPR119, APOB PPARG 393/4885PPARA 464/4885PPARD 912/4885
US-20050009892-A1 Heterocyclic compounds GPR119, LIPC, LIPE PPARG 603/4885PPARA 579/4885PPARD 646/4885
US-20040162325-A1 Heterocyclic compounds LIPE, GPR119, LIPC PPARG 701/4885PPARA 660/4885PPARD 875/4885
US-20030166697-A1 Heterocyclic compounds LIPE, GPR119, LIPC PPARG 701/4885PPARA 660/4885PPARD 875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.